Last deal

$55.6M
Local Amount - CNY 400M

Amount

Series C

Stage

02.08.2023

Date

3

all rounds

$76.1M

Total amount

General

About Company
GeneMind Biosciences is a third-generation gene sequencing system.

Industry

Sector :

Subsector :

Also Known As

GeneMind, Zhenmai Bio

founded date

01.01.2012

Company Type

For Profit

Last funding type

Series C

IPO status

Private

Description

The company is dedicated to providing better gene sequencing solutions for clinicians and researchers. Gene sequencing is a crucial aspect of medical research, and GeneMind's technology includes single molecule direct sequencing, virtual terminator, and single molecule fluorescence sequencing algorithm. Their goal is to provide affordable and effective genomic solutions for noninvasive detection, disease diagnosis, and treatment. Through unremitting research and exploration, GeneMind is breaking through the strong pass of difficulty in gene sequencing and conquering its summit.